Status of research and development of vaccines for chikungunya

Claire Smalley; Jesse H Erasmus; Charles B Chesson; David W C Beasley

doi:10.1016/j.vaccine.2016.03.076

Status of research and development of vaccines for chikungunya

Vaccine. 2016 Jun 3;34(26):2976-2981. doi: 10.1016/j.vaccine.2016.03.076. Epub 2016 Mar 26.

Authors

Claire Smalley¹, Jesse H Erasmus², Charles B Chesson³, David W C Beasley⁴

Affiliations

¹ Experimental Pathology Graduate Program, University of Texas Medical Branch, Galveston, TX, USA.
² Human Pathophysiology and Translational Medicine Graduate Program, University of Texas Medical Branch, Galveston, TX, USA.
³ Human Pathophysiology and Translational Medicine Graduate Program, University of Texas Medical Branch, Galveston, TX, USA; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.
⁴ Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA; World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: [email protected].

PMID: 27026149
DOI: 10.1016/j.vaccine.2016.03.076

Abstract

Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during the last decade has significantly expanded its geographical range and caused large outbreaks of human disease around the world. Although mortality rates associated with CHIKV outbreaks are low, acute and chronic illnesses caused by CHIKV represent a significant burden of disease largely affecting low and middle income countries. This report summarizes the current status of vaccine development for CHIKV.

Keywords: Alphavirus; Chikungunya; Emerging disease; Polyarthralgia; Vaccine.

MeSH terms

Animals
Biomedical Research / trends
Chikungunya Fever / prevention & control*
Chikungunya virus
Clinical Trials as Topic
Disease Models, Animal
Humans
Viral Vaccines / therapeutic use*

Substances

Viral Vaccines